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During the last decade, new information and reports have been published regularly describing endovascular and open
repair of ruptured abdominal aortic aneurysms, but despite this, disagreement persists over which therapy is best. At the
root of the problem is the discrepancy between the ﬁndings of multiple well-performed observational studies and a smaller
number of randomized controlled trials. Our debaters do an excellent job of summarizing the current status of the world
literature and describing their conﬂicting interpretations. (J Vasc Surg 2015;61:546-55.)PART I: ENDOVASCULAR ANEURYSM REPAIR
OFFERS NO SURVIVAL BENEFIT OVER OPEN
REPAIR FOR THE TREATMENT OF RUPTURED
ABDOMINAL AORTIC ANEURYSMSDFOR THE
ARGUMENT
Luc Dubois, MSc, MD, London, Ontario, Canada
There is no doubt that endovascular aneurysm repair
(EVAR) results in lower perioperative mortality compared
with open aneurysm repair in elective, nonruptured, pa-
tients. Multiple well-designed, large, randomized
controlled trials (RCTs) have consistently shown an
w50% reduction in the risk of 30-day mortality in favor
of EVAR for elective abdominal aortic aneurysms
(AAAs).1-3 Given the increased mortality associated with
open repair of ruptured AAAs (RAAAs), many surgeons
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in this high-risk patient group. The observational literature
has indeed shown such an improvement, with reported
mortality rates after EVAR ranging from 16% to 35%
compared with 37% to 63% after open repair.4-14 This dif-
ference in mortality has been further substantiated by large
administrative database studies,15-17 the largest of which
included data on >42,000 patients and reported a reduced
in-hospital mortality rate associated with EVAR in RAAA
patients of 26% vs 39% (P < .001).17 With the sheer
volume of observational and administrative data available
indicating a reduction in perioperative mortality, some au-
thors have argued that randomized trials comparing
EVAR and open repair are unnecessary and may even be
unethical.11,18
Many of the beneﬁts touted for EVAR in an RAAA pa-
tient seem self-evident: reduced physiologic stress with
avoidance of aortic cross-clamping and ischemia-
reperfusion injury, ability to perform the procedure under
local anesthetic, reduced hypothermia, and reduced blood
loss. Yet, despite these considerations and the weight of the
previous observational data, RCTs to date have shown no
difference in early mortality between endovascular and
open repair in RAAA patients. Certainly, these results
would seem surprising to many surgeons; however, one
cannot ignore the evidence.
Two of the trials are smaller and may be criticized for
being underpowered. The ﬁrst trial, from the United
Kingdom, included just 32 patients and found the 30-day
mortality rate was similar between open and EVAR (53%
in both groups).19 Similarly, in the Dutch trial, which
included results for 116 patients, there was no difference
in 30-day mortality between EVAR and open repair (21%
vs 25%).20 The latter trial has been criticized for being
too selective because it excluded patients who were too
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anatomy unsuitable for endovascular repair.
These criticisms were addressed by the recent publi-
cation of early results from the Immediate Management
of the Patient With Rupture: Open vs Endovascular
Repair (IMPROVE) trial. This trial was not only larger
and appropriately powered but was also designed in a
pragmatic style that strove to include all patients who
presented to the hospital with a suspected diagnosis of
RAAA. In doing so, the investigators ensured generaliz-
ability of their results. The IMPROVE trial clearly
demonstrated, based on the analysis of 613 patients,
that a nonselective approach to endovascular aneurysm
repair in RAAA patients resulted in equivalent 30-day
mortality compared with open repair (35.4% vs 37.4%,
P ¼ .62).21 Some may criticize this trial for its pragmatic
design, where patients were randomized to a therapeutic
approach rather than to a speciﬁc procedure. Patients
were randomized once a clinical diagnosis of suspected
RAAA was made, without knowledge of their anatomic
suitability for EVAR. Patients randomized to the EVAR
strategy arm underwent a CT scan to determine anatomic
suitability and, if suitable, underwent EVAR; otherwise,
they underwent open repair. This method of allocation
resulted in only 64% of those in the EVAR group being
anatomically suitable, and 13% of patients had a diagnosis
other than RAAA. These limitations were necessary con-
sequences of the pragmatic trial design, ultimately
ensuring that both treatment strategies were comparable
and free of selection bias and confounding.
All RCTs to date have shown no difference in mortality
between open and endovascular repair in ruptured patients.
How can there be such a discrepancy between the random-
ized controlled literature and observational data?
Why observational studies are misleading. Regard-
less of the number of observational studies showing
improved mortality with EVAR, they all suffer from the
same inherent biases that tend to favor EVAR. The most
recent and complete meta-analysis of the observational
literature comparing EVAR and open repair in ruptured
patients found most studies suffered from severe selection
bias.22 The key factors determining why many surgeons in
these studies offer EVAR to ruptured patients (stability
enough to have imaging and favorable anatomy) are also
both strong independent predictors of postoperative mor-
tality. The effect of preoperative hemodynamic instability on
mortality from RAAAs is well known.23 This inherently fa-
vors the EVAR group by restricting EVAR to those patients
who have stable blood pressure at baseline and an improved
survival. Similarly, patients in observational studies with
short aortic necks (<10 mm) and challenging iliac anatomy
(tortuosity, calciﬁcation) tended to have open repair. These
same anatomic factors that make EVAR unfavorable also
make open repair more complex and increase perioperative
mortality. In a recent abstract using the IMPROVE data,
investigators noted that mortality was associated with the
aortic neck length in the EVAR and open treatment groups.
In those patients with aortic necks between 5 and 9mm, the30-day mortality was 63% for EVAR and 44% for open
repair, whereas in those with aortic neck lengths >30 mm,
mortality in both groups wasw25%.24 Other authors have
also shown EVAR anatomic suitability is a strong indepen-
dent predictor of mortality after open repair of RAAA.25
In addition to the effect of selection bias, the observa-
tional studies also suffer from a lack of blinded outcome as-
sessments, selective reporting of results, and publication
bias.22 Publication bias may be particularly important
because centers with poor results after EVAR for ruptured
patients would be unlikely to publish those results. Even
those authors who are strong advocates for an aggressive
EVAR-ﬁrst policy for RAAA have admitted that many of
the centers reporting their results for RAAA limit the pro-
cedure to hemodynamically stable patients or those with
“contained” ruptures and that “. it is totally invalid to
compare the lower procedural EVAR mortality rates with
those for open repair.”26 I would agree and state that the
only valid comparison comes from properly designed, pow-
ered, and reported RCTs such as IMPROVE.
Administrative and clinical database studies not only
suffer from the same limitations but are also compounded
by errors in diagnostic coding, missing data on key con-
founders (hypotension, level of consciousness, anatomy),
and lack of information on the volume and experience of
the surgeons performing the interventions.17,27 These lim-
itations further compromise the comparison between
EVAR and open repair for RAAA.
Observational studies often overestimate the beneﬁt
of new interventions compared with RCTs.28 The litera-
ture is ﬁlled with examples where RCTs have contra-
dicted the results of observational studies and tempered
early enthusiasm for new procedures. Classic examples
from the vascular literature include the disappointing re-
sults of prosthetic bypasses for leg ischemia compared
with vein grafts as reported by Veith et al29 in the
1980s, the harmful effects of extracranial-intracranial
arterial bypass in patients with cerebrovascular disease,30
and the lack of beneﬁt to preoperative coronary artery
revascularization before vascular surgery.31 Similar to
these examples, the mortality beneﬁt ascribed to EVAR
in RAAA patients by observational studies has not been
conﬁrmed by RCTs. Despite all of EVAR’s theoretical
advantages and presumed effectiveness based on uncon-
trolled data, it seems that favorable anatomy, hemody-
namic instability, and overall patient health status exert
a greater inﬂuence on postoperative mortality in patients
with RAAA than the method of repair.
It is evident that surgeons expected to ﬁnd a mortality
beneﬁt to EVAR in ruptured patients. The language used
in some of the publications surrounding the topic speaks
toward this investigator bias: “The ﬁnding that mortality
rates were comparable in open and endovascular groups
was disappointing.”19; however, the existing level I evi-
dence quite clearly shows that EVAR does not confer a sur-
vival advantage to patients with RAAA. Misinterpreting
this literature could lead to troubling consequences for pa-
tient care.
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OFFERS NO SURVIVAL BENEFIT OVER OPEN
REPAIR FOR THE TREATMENT OF RUPTURED
ABDOMINAL AORTIC ANEURYSMSDAGAINST
THE ARGUMENT
Dieter Mayer, MD, Zoran Rancic, MD, Frank J.
Veith, MD, and Mario Lachat MD, Zurich, Switzerland;
New York, NY; and Cleveland, OhioEndovascular aneurysm repair (REVAR) for ruptured
abdominal aortic aneurysm (RAAA) has proved superior
to open repair (ROR) in (most) comparative single-
center and multicenter studies. However, considerable
controversy exists, and sceptics continue to claim that
REVAR is no better than ROR, citing the small, random-
ized controlled Nottingham trial1 and several nonrandom-
ized trials2-4 that found no beneﬁt for REVAR compared
with ROR. In addition, these sceptics are also critical of
the superior REVAR results being achieved in some single
centersdas well as in population-based studiesdas being
simply down to selection bias (ie, selecting the best patients
for REVAR) and possible high turn down rates (ie, patients
who are denied any invasive treatment).
Results of three multicenter European randomized
controlled trials (RCTs) of REVAR compared with ROR
have recently been reported and added to the debate. One
is from the Netherlands (AJAX [Acute Endovascular Treat-
ment to Improve Outcome of Ruptured Aortoiliac Aneu-
rysms] trial), another from France (ECAR [Endovasculaire
vs Chirurgie dans les Anevrysmes Rompus] trial), and the
third is from the United Kingdom (IMPROVE [Immediate
Management of the Patient With Rupture: Open vs Endo-
vascular Repair] trial).5-7 Not surprisingly, most observers
hoped that these contemporary RCTs would help resolve
the REVAR vs ROR controversy regarding the optimal
treatment of ruptured abdominal aortic aneurysm.
What is the evidence from the RCTs? In summary,
all four RCTs observed no signiﬁcant difference in short-
term (30-day) mortality between REVAR and ROR. Does
this, therefore, mean that opponents of REVAR superiority
have been proven to be right and that this controversy is
settled? If you are a believer in RCTs, it should be. How-
ever, a critical appraisal of all four RCTs reveals a number of
methodologic issues that justify an alternative interpretation.
The trial details, methodologies, and case selection protocols
are summarized in Table I and in the text below.
The Nottingham trial (United Kingdom). This sin-
gle-center RCT was analyzed on an intention-to-treat ba-
sis.1 The trial recruited 103 patients, of whom only 32
(31%) were randomized. Reasons for not randomizing
patients included not ﬁt for ROR, died in the Accident and
Emergency Department before randomization, unable to
give informed consent (unconscious), age, refusal to un-
dergo surgery, no team available, and surgeon thought
open repair to be more appropriate. In this RCT (with 70%
of potential patients being excluded), the 30-day mortality
was 53% for both REVAR and ROR.
The authors expressed disappointment with REVAR
and concluded that the bad results in the REVAR group
(compared with those in the literature) were a reﬂection
of the fact that there was no case selection in RCTs
compared with nonrandomized cohorts from earlier
studies. This trial was, ultimately, ﬂawed because of its
small size, the high proportion of exclusions, and the fact
that only 15 patients underwent REVAR.
The ECAR trial (France). The preliminary results of
this multicenter French RCT5 have been presented at
Table I. Methodology and limitations of four European randomized controlled trials (RCTs)
Study Country
Centers
(No.) Start
End
Randomization
Patients
planned
(No.)
Patients recruited, No.
LimitationsSuspected Deﬁnitive Total REVAR ROR
Nottingham1 UK 1 09/2002 NA 12/2004 Unclear 100 32 15 17 Inclusion: high
exclusion rate
(69%)
Team availability
ECAR5 France 14 12/2007 12/2010 01/2013 Per week,
if stable
(after CTA)
160 107 56 51 Patient selection:
stable patients
only
Operator
experience: 15
elective EVAR
AJAX6 Netherlands 3a 04/2004 10/2007
08/2008
10/2010
02/2011 Block by
computer
(after CTA)
80 (2004)
112 (2008)
116 57 59 Patient selection:
only stable
patients could
be referred to
3 trial centers
Rupture diagnosis:
moderate
interobserver
agreement
(k ¼ 0.59)
Anatomic
suitability: fair
interobserver
agreement
(k ¼ .39)
Study: possibly
underpowered
IMPROVE7 UK 30 09/2009 03/2013 07/2013 Block per
telephone
(before CTA)
600 613 316 297 Team availability:
66% of the week
Team experience:
20 EVAR/a,
5 REVAR done
Inclusion before
CTA: inclusion
of nonsuitable
patents or
non-RAAA
AJAX, Acute Endovascular Treatment to Improve Outcome of Ruptured Aortoiliac Aneurysms; CTA, computed tomography angiography; ECAR,
Endovasculaire vs Chirurgie dans les Anevrysmes Rompus; IMPROVE, Immediate Management of the Patient With Rupture: Open vs Endovascular Repair;
NA, not applicable; RAAA, ruptured abdominal aortic aneurysm; REVAR, ruptured endovascular aneurysm repair; ROR, ruptured open repair; UK, United
Kingdom.
aOnly 3 of the 10 centers involved in AJAX (the “trial centers”) offered both REVAR and ROR.
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randomized only stable patients (systolic blood pressure on
arrival >80 mm Hg, no vasopressive drugs administered)
with suitable EVAR morphology (proximal neck length
>10 mm, neck diameter <32 mm, neck angulation <90).
Only 107 patients were randomized. To date, no signiﬁcant
statistical difference in 30-day mortality between the two
groups has been observed, although reasonably low mortality
rates were reported for both REVAR and ROR. Interest-
ingly, among seven of the 14 recruiting centers, only w50%
of patients were eligible for randomization (range, 35%-63%).
The AJAX trial (Netherlands). This multicenter
RCT randomized 116 of 520 RAAA patients (22%) in
the Amsterdam region and analyzed outcomes on an
intention-to-treat basis.6 AJAX found no signiﬁcant dif-
ference in the primary composite end point of death/se-
vere complications (REVAR, 42%; ROR, 47%) or death
(REVAR, 21%; ROR, 25%). However, meaningful inter-
pretation of these data is difﬁcult because almost 80% of
patients were not randomized, interobserver agreement onthe computed tomography (CT) diagnosis of rupture was
imperfect, and EVAR-suitable but severely unstable pa-
tients were not transferred to centers capable of doing
REVAR as well as ROR.
The authors also speculated that REVAR outcomes
were negatively inﬂuenced by a high intraoperative conver-
sion rate to ROR (14%), mainly due to access failure and
type I endoleaks, as well as the inexperience of some of
the REVAR operators. In addition, morbidity was signiﬁ-
cantly lower for REVAR (less postoperative mechanical
ventilation, less blood loss, and less moderate to severe
renal insufﬁciency).
The IMPROVE trial (United Kingdom). The au-
thors of this multicenter RCT claimed it was both “prag-
matic” and to have a “real-world design.”7 IMPROVE
randomized 623 of 1275 candidates (49%) with a clinical
diagnosis of ruptured abdominal aortic aneurysm to
REVAR or ROR. CT angiography (CTA) was performed
after randomization and was optional for patients allocated
to ROR. This meant that when patients were allocated to a
JOURNAL OF VASCULAR SURGERY
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CTA, they were then switched to ROR but remained within
the REVAR strategy group for intention-to-treat analyses.
The difference in 30-day mortality between the
REVAR and ROR groups (35% vs 37%) was not signiﬁcant;
however, women allocated to REVAR had a signiﬁcantly
lower 30-day mortality than in the ROR group (37% vs
57%; males: 35% vs 32%). In addition, the average length
of stay in critical care and in the hospital was signiﬁcantly
shorter for REVAR patients, and they were discharged
more often to home than those in the ROR group (94%
vs 77%). The authors concluded that in the largest prag-
matic randomized trial, 30-day mortality and costs were
similar for the EVAR and ROR groups.
Close inspection of these RCTs suggests that they
may be ﬂawed and not conclusive regarding the
REVAR vs ROR controversy. RCTs are thought to be
the most rigorous method for determining whether a
cause-and-effect relationship exists between treatment
and outcome and for assessing the (cost) effectiveness of a
treatment.8 However, RCTs can have ﬂaws and imperfec-
tions that may render them invalid. One such ﬂaw is
randomization. All or most of the patients with a given
condition must be randomized. Exclusion of many (or
most) patients can invalidate an otherwise good trial, and
high exclusion rates (51%-78%) were evident in all four
European RCTs (Table I). In addition, treatment alloca-
tion after CTA in the IMPROVE trial led to the para-
doxical situation where patients who were randomized to
REVAR (but who were found to be unsuitable after CTA)
or who were found to have diagnoses other than RAAA
had to remain within the REVAR limb of the trial (inten-
tion-to-treat analysis) despite receiving ROR or other
treatments. The 30-day mortality rates for the latter two
cohorts of patients were much higher than the 25%
observed after REVAR (ROR, 38% vs other, 33%).
The authors of IMPROVE claim that this trial repre-
sented a real-world setting. We would strongly challenge
this statement. Optimal treatment dictates that manage-
ment can only be determined once a correct diagnosis
has been made. Almost half the patients in the EVAR
limb were deemed unsuitable for REVAR and then under-
went ROR. How can this be a fair evaluation of REVAR?
Interestingly, a per-protocol analysis shows a different pic-
ture, with a 30-day mortality of 32% for REVAR compared
with 41% for ROR. Moreover, an analysis that excluded
those patients who did not undergo invasive treatment
showed the 30-day mortality rate was 26% for REVAR vs
37% for ROR.
The ECAR and AJAX trials performed CTA before
randomization, thereby allowing better randomization.
However, these two trials excluded from randomization
subgroups of RAAA patients who were hemodynamically
unstable and technically difﬁcult or at high risk. Accord-
ingly, these trials did not allow a demonstration of the
advantages of REVAR in the higher-risk patients who
would be expected to beneﬁt most from the less invasive
procedure.Furthermore, in studies dealing with rapidly advancing
medical technology, outdated devices or techniques, or
both, may quickly render invalid the results of an RCT.
The three most recent European RCTs encountered prob-
lems with delays in recruitment and some took >10 years
to complete. None used any of the adjunctive technologies
that have emerged during the past few years and that
constitute an important part of the armamentarium in
highly specialized centers that are otherwise accused of be-
ing biased.9,10 Several large RCTs in the management of
carotid disease have now been challenged and new RCTs
demanded as novel therapeutic options (conservative and
endovascular) have emerged after the trials were
completed.11 In addition, soft criteria, such as “feasibility”
or “inoperability,” are difﬁcult to standardize and interpret,
and even hard criteria, such as rupture, have been shown to
be subject to important interobserver variability.
Although the feasibility of REVAR has been claimed to
be onlyw40% to 60%,1,5-7,12-15 we recently showed, by us-
ing adjunctive procedures (eg, parallel grafts, coiling, Onyx
[ev3 Endovascular, Inc. Plymouth, Minn], etc), that nearly
100% of RAAAs can be treated by REVAR. If the recently
published European RCTs had used even some of these ad-
juncts and strategies, the REVAR results would undoubt-
edly have been better. In addition, denial of invasive
treatment and conservative or palliative treatment (ie, min-
imal therapy while awaiting death) would also have been
much less than was observed in the RCTs. In this regard,
nontreatment rates up to 60% have been published.16-18
In the IMROVE trial, 57% of those patients who were
not randomized did not undergo any form of repair,7 a
fact that undermines the validity of a trial when judging
the effect of a treatment like REVAR. Lastly, team avail-
ability and experience has been an issue in all of the
RCTs. We strongly question the evaluation of a treat-
ment modality if the availability of expertise is missing
because of specialist availability (IMPROVE: 66% of the
week) or a lack of experience, as noted in the prerequi-
sites in Table I.19,20
There is evidence outside RCTs to support the
superiority of REVAR. The authors of IMPROVE
concluded that a disparity remains between evidence derived
from well-equipped, highly specialized single centers, sys-
tematic reviews, and national data sets. Does this mean that
the latter are of no value, wrong, or even useless? In an
important article by Benson et al,21 the results of observa-
tional studies were compared with those of RCTs. In 17 of
19 miscellaneous treatments analyzed, the estimates of the
treatment effects from observational studies and RCTs were
similar. In only two of the 19 analyses did the combined
magnitude of the effect in observational studies lie outside
the 95% conﬁdence interval for the combined magnitude in
the RCTs. They concluded that little evidence was found
that estimates of treatment effects in observational studies
reported after 1984 are consistently larger than or qualita-
tively different from those obtained in RCTs.
In a more recent study, Shikata et al22 compared the
results of RCTs vs observational studies in a meta-analysis
Table II. Characteristics of studies evaluating the outcome after endovascular (REVAR) and open repair (ROR) of a
ruptured abdominal aortic aneurysm (RAAA)a
First author Year
Study/
registry
Study
design Period
RAAA
REVAR ROR
REVAR 30-day mortality, % (range)
Total Randomized % (range) REVAR ROR Overall
Hinchliffe1 2006 Nottingham RCT 2002-2004 103 32 15 17 47 53 53 53
DesGranges5 2010 ECAR RCT 2007-2013 e 107 56 51 e e e e
Reimerink6 2013 AJAX RCT 2004-2011 520 116 57 59 49 21 25 e
Powell7 2014 IMPROVE RCT 2009-2013 1275 613 316 297 52 35 37 e
Bown23 2002 SR & MA 1955-1998 10,809 0 10,809 0 e 48 48
Visser24 2007 SR & MA 1994-2006 478 148 330 31 22 38 41
Harkin25 2007 SR & MA 1999-2006 e 876 17 (34-100) 18b 34 21
Mastracci26 2008 SR & MA 1994-2006 3213 436 0 100 21 e 21
Sadat27 2008 SR & MA 1994-2007 7040 730 6310 10 27b 31 29
Rayt28 2008 SR & MA 1950-2007 982 982 0 100 24 e 24
Takagi29 2011 SR & MA 1995-2006 e 42,888 e e NAc e e
Reimerink30 2013 SR & MA 1977-2012 14,670 e e e e 80 (74-86)
van Beek31 2014 SR & MA 1990-2012 72,614 e e e 29 40 34
McPhee32 2008 NIS Registry 2001-2006 27,750 3192 24,559 12 32b 41 36
Lesperance33 2008 NIS Registry 2001-2004 28,123 2390 25,733 (6-11) 31b 42 (29-43)
Giles34 2009 NIS Registry 2000-2005 e 2323 26,106 8 33b 41 41
Davenport35 2010 NSQIP Registry 2005-2007 427 99 328 23 22b 37 e
Edwards36 2014 Medicare Registry 2001-2008 10,998 1126 9872 (6-31) 34b 48 e
Veith37 2009 MC 2002-2006 1443 680 763 47 20b 36 28
Mayer9 2012 MC 1998-2011 473 198d 163d 57 16b 37 33
AJAX, Acute Endovascular Treatment to Improve Outcome of Ruptured Aortoiliac Aneurysms; ECAR, Endovasculaire vs Chirurgie dans les Anevrysmes
Rompus; IMPROVE, Immediate Management of the Patient With Rupture: Open vs Endovascular Repair; MC, multicenter study; NA, not applicable; NIS,
Nationwide Inpatient Sample; NSQIP, National Surgical Quality Improvement Project; SR & MA, systematic review and meta-analysis.
aValues are numbers unless stated otherwise.
bStatistically signiﬁcant difference.
cStatistically signiﬁcant difference, but no numbers given, just a statement in the text.
d1998-2009 (period when EVAR and ROR were done, before “EVAR-only” approach).
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fourth of the observational studies gave different results
than randomized trials. However, the authors stated that
observational studies offer several distinct advantages over
RCTs, including lower cost, greater timeliness, and a
broader range of patients, and that these beneﬁts remain
worthy of attention in real-world clinical settings, particu-
larly where random allocation is not easily accepted by cli-
nicians or patients. Systematic reviews and meta-analyses of
non-RCT, provided they are done properly, are important
tools for consolidating data from high-quality observational
studies. Table II provides an overview of the most impor-
tant studies and their outcomes.
Systematic reviews and meta-analyses. In a 2002
meta-analysis of outcomes over ﬁve decades, Bown
et al23 showed that the mortality rates after ROR had not
improved, despite progress in anesthesiology and inten-
sive care practice. Various systematic reviews and meta-
analysis have been published since then covering
REVAR, ROR, or both (Table II).23-31 In 2014, van
Beek et al31 published the most comprehensive meta-
analysis (involving >70,000 patients after screening
almost 6000 references) and ﬁnally included three RCTs,
eight administrative registries, and 21 observational
studies with >50 patients. In summary, although it is
accepted that some groups only used REVAR in “favor-
able” RAAA patients, in not one of the nine published
systematic reviews was EVAR inferior to ROR. There was
a tendency toward superiority favoring REVAR in all,whereas three showed REVAR was superior. The authors
concluded that EVAR was not inferior to ROR, that
speciﬁc patient subgroups should be carefully studied (eg,
women, those with hostile anatomy), and that some of
the adjunctive technologies adopted within our own
EVAR-only approach9 would be promising.
Registries. Administrative registries are often viewed
with considerable suspicion. However, they are probably
best at representing the real-world scenario, rather than
an RCT such as IMPROVE. In all ﬁve registries analyzed
and published, REVAR outperformed ROR.32-36 Inter-
estingly, results clearly show a learning curve, with out-
comes becoming better in the later years of analysis,
suggesting that REVAR has even greater potential than has
been demonstrated so far.
Multicenter (observational) studies. Two multi-
center studies of particular interest are included in Table II:
The collected world and single-center experience with
EVAR treatment of RAAAs pooled data from 49 centers.37
Thirteen of 49 centers adhered to an “EVAR-whenever-
possible protocol” and treated 1443 patients (REVAR, 680;
ROR, 763). REVAR proved to be signiﬁcantly better than
ROR, with 30-day mortality of 19.7% vs 36.3%. The second
study, published by Mayer et al9 in 2012, was the ﬁrst (two-
center) study to show that all RAAA patients can be safely
treated by EVAR, with low mortality and turn down rates
(4%) for infrarenal and juxtarenal RAAA, provided there is an
EVAR-only approach protocol and certain adjunctive pro-
cedures and materials are available (see below).
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group has published numerous scientiﬁc and technologic
papers on the performance of REVAR since 1998, with
excellent outcomes and low turn down rates.9,19,20,37-51
From the beginning, a detailed protocol was established
that has been reﬁned over the years. This “Zurich algo-
rithm”20,42,52 focuses attention on ﬁve key points: hemo-
dynamics, imaging, procedure, abdominal compartment
syndrome (ACS), and teamwork.
Hemodynamics. Hypotensive hemostasis, balloon
control when necessary, and local anesthesia have been
key factors in inﬂuencing hemodynamics within our ﬁrst
protocol and the subject of many publications.19,20,38,53,54
Interestingly, most of these factors are now being recog-
nized by other authors more than a decade later. We are
particularly supportive of the importance of performing
REVAR under local anesthesia (currently used in 80% of
our patients), and IMPROVE also reported lower mor-
tality rates where local anesthesia was used.55 However,
most patients being randomized within the European
RCTs underwent their intervention under general anes-
thesia, leading us to question whether those RCTs remain
valid or conclusive.
Imaging. Preoperative imaging, preferably thoracoab-
dominal CTA, should always be done in RAAA patients,
especially when under consideration for REVAR or other
adjunctive procedures.9,19,20, The patient should undergo
a quick clinical review and insertion of large-bore periph-
eral catheters before quickly undergoing a CTA that will be
evaluated simultaneously by the radiologist and the
vascular surgeon while the patient undergoes further
preparation.
Procedures. We strongly advise performing REVAR
in a “daily business” manner and atmosphere.19,20 If the
team is used to implanting bifurcated stent grafts, these
tactics should not change to aortomonoiliac devices and
vice versa. In the future, simulation training will also as-
sume an important role for improving technical skills and
outcomes after REVAR.56
Abdominal compartment syndrome. ACS is a major
killer after successful REVAR or ROR and is still frequently
underdiagnosed.42,45,47 During the last 15 years, the rate
of ACS in our REVAR population has remained constantly
between 20% and 25% (a prevalence supported by other
groups). Left untreated, most of these patients will die.
Surprisingly, ACS did not seem to play a major role in the
new European RCTs, where the ACS rate was <10% or
not mentioned. We question whether underdiagnosis and
nontreatment of ACS could have negatively inﬂuenced the
results of the latest RCTs. In any case, all staff dealing
with RAAA patients should be aware of the condition
and know the new deﬁnitions and recommendations of
the World Society of the Abdominal Compartment
Syndrome.45,57
Teamwork. REVAR is ideally performed by an inter-
disciplinary team of vascular surgeons, radiologists, anes-
thetists, and specialized scrub nurses.19 A standardized
patient pathway for RAAA management and a reliable/experienced multidisciplinary team are the keys toward
improving patient outcomes. REVAR team training using
high-ﬁdelity simulation may be helpful in allowing less
experienced colleagues to learn, practice, rehearse,
improve, and maintain team-based knowledge, technical,
and human factor skills, and team attitudes to manage
REVAR successfully.56
CONCLUSIONS
To us, REVAR is clearly the best treatment option for
patients with an RAAA, provided the skills and materials to
do it are available. RCTs comparing REVAR and ROR are
difﬁcult to do, and those that have been published are
misleading. Our opinion is that resources would be better
directed toward developing endovascular skills and team
training rather than planning for further RCTs.
We thank Dr Lyubov Chaykovska for her help during
the literature search and for creating the Tables for this
article.
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Compartment Syndrome. Intensive Care Med 2013;39:1190-206.EDITORS’ COMMENTARYThomas L. Forbes, MD, and A. Ross Naylor, MBChB, MD, FRCS, Toronto, Ontario, Canada; and Leicester,
United KingdomDuring this era of evidence-based medicine where random-
ized controlled trials (RCTs) are king, we are constantly in search
of level I evidence to guide us. The area of ruptured abdominal
aortic aneurysms (RAAAs) is no exception, but unfortunately,
the attainment of robust level I data has been elusive. The difﬁculty
in performing such a study is one area where our authors agree.
The recent Dutch attempt at an RCT, Amsterdam Acute
Aneurysm (AJAX) trial, failed to show a difference in mortality be-
tween open and endovascular aneurysm repair (EVAR) groups.1
However, before rushing to use this information to disparage
endovascular repair for RAAAs, we need to remember that these
ﬁndings were limited to the small subgroup of 20% of RAAA pa-
tients who were hemodynamically stable and anatomically suitable
for EVAR as determined by a preoperative computed tomography
(CT) scan. Given these inclusion criteria. It is little wonder that no
difference was observed.
The more recent Immediate Management of the Patient with
Ruptured Aneurysm: Open vs Endovascular Repair (IMPROVE)
trial was of a much different design.2 Rather than comparing
EVAR and open repair in a subset of RAAA patients, this prag-
matic trial compared an EVAR approach (CT scan and EVAR, if
anatomically suitable) with an open repair approach (open repair,
with or without CT scan) in all patients with a clinical diagnosis
of an RAAA. Approximately half of the RAAA patients presenting
to study sites were randomized, with a common reason for nonin-
clusion being unavailability of an EVAR team. Although the study
investigators noted a trend toward improved results with EVAR in
women and with the use of local anesthesia, the 30-day mortality
rates were similar between these two approaches by intention-to-
treat analysis.
In the absence of convincing RCTs, proponents of EVAR for
RAAA have relied on single-center and multicenter experiences
comparing open and endovascular repair. As outlined in the
debate, EVAR opponents point to the inherent biases in these re-
ports and the selective reporting of results. Information regarding
the choice between open and endovascular repair in these studies is
often missing or variable. An exception is the only report of com-
plete adoption of EVAR for all RAAA repairs that resulted in a sig-
niﬁcant reduction in perioperative mortality compared with the
previous era of EVAR when possible.3Of course, all of these reports, RCTs or otherwise, offer
limited information regarding the entire RAAA cohort of patients
because they include only those who undergo an attempted repair.
This is not an unimportant issue, because a recent population-
based study reported that 20% of RAAA patients in the United
States and 41% in England did not receive any repair.4 Lower mor-
tality after the intervention was associated with larger hospital case
loads, admission on weekdays, and increased use of EVAR.
Our authors would surely agree that no repair is a poor choice
in most patients compared with any type of intervention, whether
it be open repair or EVAR. It is with these patients who are turned
down for repair where the greatest potential beneﬁt exists, some of
whom are not transferred when open repair is the only option and
they are deemed too high risk. The wider adoption of EVAR for
RAAA has the potential to create further high-volume centers
with consistently available EVAR and open surgical expertise
resulting in transfer of more patients and reduction in these turn
down rates, regardless of the eventual method of repair. For this
reason, wider adoption of EVAR for RAAA should be encouraged.REFERENCES
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